of Hematology, Sultan 2. Abdülhamid Han Training and Research Hospital,
Health Sciences University, Istanbul, Turkey.
2 Department of Pulmonology, Sultan 2. Abdülhamid Han Training and Research Hospital, Health Sciences University, Istanbul, Turkey.
| This is an Open Access article distributed
under the terms of the Creative Commons Attribution License
(https://creativecommons.org/licenses/by-nc/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Background and objective:
Patients with latent tuberculosis infection (LTBI) receiving
chemotherapy for hematological malignancy (HM) are at high risk of
developing active tuberculosis (TB) infection. The aim of this study is
to show real-life data and results of the T-SPOT test and preventive
isoniazid (INH) therapy in pre-chemotherapy LTBI screening in the HM
Materials and Methods
|Figure 1. Flowchart of patients with hematological neoplasm. 297 patients with HM were evaluated. Patients whose data could not be obtained (n=41), T-SPOT test could not be performed at the time of diagnosis of HM (n=34), patients with prior TB infection (n=12), and patients diagnosed with active TB infection concurrently with HM diagnosis (n=1) were excluded from the study. 209 patients with HM who had a T-SPOT test for LTBI were included.|
|Table 1. Clinical and sociodemographic characteristics by T-SPOT groups.
Ethics Committee Approval